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Background and Objective 
Current prototypes of closed-loop systems for glucose control in type 1 diabetes mellitus, also 
referred to as artificial pancreas systems, require a pre-meal insulin bolus to compensate for 
delays in subcutaneous insulin absorption in order to avoid initial post-prandial 
hyperglycemia. Computing such a meal bolus is a challenging task due to the high intra-
subject variability of insulin requirements. Most closed-loop systems compute this pre-meal 
insulin dose by a standard bolus calculation, as is commonly found in insulin pumps. 
However, the performance of these calculators is limited due to a lack of adaptiveness in front 
of dynamic changes in insulin requirements. Despite some initial attempts to include 
adaptation within these calculators, challenges remain. 
 
Methods 
In this paper we present a new technique to automatically adapt the meal-priming 
bolus within an artificial pancreas. The technique consists of using an adaptive bolus 
calculator based on Case-Based Reasoning and Run-To-Run control, within a closed-loop 
controller. Coordination between the adaptive bolus calculator and the controller was required 
to achieve the desired performance. For testing purposes, the clinically validated Imperial 
College Artificial Pancreas controller was employed.  
The proposed system was evaluated against itself but without bolus adaptation. The UVa-
Padova T1DM v3.2 system was used to carry out a three-month in silico study on 11 adult 
and 11 adolescent virtual subjects taking into account inter-and intra-subject variability of 
insulin requirements and uncertainty on carbohydrate intake. 
 
Results 
Overall, the closed-loop controller enhanced by an adaptive bolus calculator improves 
glycemic control when compared to its non-adaptive counterpart. In particular, the following 
statistically significant improvements were found (non-adaptive vs. adaptive). Adults: mean 
glucose 142.2±9.4 vs. 131.8±4.2 mg/dl; percentage time in target [70, 180] mg/dl, 82.0±7.0 
vs. 89.5±4.2; percentage time above target 17.7±7.0 vs. 10.2±4.1. Adolescents: mean glucose 
158.2±21.4 vs. 140.5±13.0 mg/dl; percentage time in target, 65.9±12.9 vs. 77.5±12.2; 
percentage time above target, 31.7±13.1 vs. 19.8±10.2. Note that no increase in percentage 
time in hypoglycemia was observed. 
 
Conclusion 
Using an adaptive meal bolus calculator within a closed-loop control system has the potential 
to improve glycemic control in type 1 diabetes when compared to its non-adaptive 
counterpart. 
 




Type 1 diabetes mellitus (T1DM) is an autoimmune condition characterized by elevated 
blood glucose levels due to the lack of endogenous insulin production. People with T1DM 
require exogenous insulin delivery to regulate glucose. Current therapies for T1DM 
management include the administration of multiple daily injections or continuous insulin 
infusion with pumps. However, such therapies are still suboptimal and require constant 
adjustment by the person with T1DM and carers. A closed-loop control system consisting of a 
continuous glucose sensor, an insulin pump and an algorithm that computes the required 
insulin dose at any instant [Trevitt 2015], has the potential to improve glucose control in 
people with T1DM. 
Recent studies evaluating a closed-loop system for automatic glucose control in type 1 
diabetes mellitus (T1DM), also referred to as artificial pancreas, have demonstrated safety 
and efficacy during in-clinic and ambulatory trials [Thabit 2015]. 
Ideally, a completely automated closed-loop control system would not require any user 
intervention, for example to announce meals, and would react in real-time to changes in blood 
glucose. However, delays in subcutaneous insulin absorption have led many investigators to 
include the use of a pre-meal insulin bolus within the artificial pancreas [Doyle 2014] (Figure 
1). The calculation of such pre-meal insulin bolus is usually done by means of a simple bolus 
calculator [Schmidt 2014], found in most insulin pumps. However, accurately computing a 
meal bolus remains a challenging task due to the high variability of insulin requirements in 
T1DM [Visentin 2015] and the uncertainty in carbohydrate estimations [Brazeau 2013]. 
 
Figure 1. Block diagram of a closed-loop system for glucose control incorporating a meal 
bolus calculator. 
 
The utilisation of an adaptive meal-priming bolus within an artificial pancreas has previously 
been proposed by El-Khatib et. al [El-Khatib 2015] showing some encouraging clinical 
results relative to an entirely reactive system with no meal-priming boluses. Such adaptive 
meal-priming insulin bolus consists of automatically adjusting the size of breakfast, lunch, 
and dinner doses by administering 75% of the average prandial insulin provided for previous 
meals at that time of day. However, this method has the limitation that assumes that 
carbohydrate intakes are fairly similar every day, which is not always the case. It also does 
not take into consideration intra-subject insulin variability due to factors such as exercise, 
alcohol, stress, weather, hormones, and variation in macronutrient meal composition. 
Outside the context of the artificial pancreas, the concept of an adaptive bolus calculator has 
been proposed Palerm et al. [Palerm 2007] by mean of Run-to-Run control [Wang 2009]. 
Although showing some promising preliminary clinical results, this approach has the 
limitation of being very sensitive to meal composition due to the employed control law. In 
[Tuo 2015], Tuo et al. propose a similar technique based on a high order Run-to-Run control 
scheme. The problem with this approach is that the employed control law does not account 
for hypoglycemia. Similar to the work proposed by El-Khatib et. al [El-Khatib 2015], these 
two approaches do not consider factors affecting insulin requirements, other than circadian 
variations. 
In this paper, we present a novel technique to automatically adjust the meal-priming 
bolus within an artificial pancreas. For this purpose, a Run-to-Run algorithm incorporating a 
new control law, which avoids some of the limitations of previously proposed techniques, is 
introduced. Then, Case-Based Reasoning [Aamodt 1994], an artificial intelligence technique 
which solve new problems based on the solutions of similar past problems, is employed to 
account for intra-subject insulin sensitivity variability. 
The proposed technique is based on an existing adaptive bolus calculator, referred to as 
Advanced Bolus Calculator for Diabetes (ABC4D) [Herrero 2015a, Herrero 2015b, Pesl 
2016a], which has been modified to fulfill the requirements of a closed-loop system for blood 
glucose control.  
For evaluation purposes, a novel version of the clinically validated Imperial College Bio-
inspired AP controller [Herrero 2012, Reddy 2014, Reddy 2015] (see Appendix A) and the 





2.1 - Insulin Bolus Calculator  





− 𝐼𝑂𝐵,  (1) 
where B (U) is the total calculated bolus, CHO (g) is the estimated amount of ingested 
carbohydrates, ICR (g/U) is the insulin-to-carbohydrate-ratio, GM (mg/dl) is the measured 
glucose at meal time, GT (mg/dl) is the glucose target to be achieved, ISF (mg/dl/U) is the 
insulin sensitivity factor, and IOB (U) is the insulin-on-board, which represents an estimation 
of the remaining active insulin in the body [Schmidt 2014]. 
The parameters of a bolus calculator (ICR, ISF) can be manually adjusted based on the time 
of the day (i.e. breakfast, lunch, dinner), exercise, or variation in hormonal cycles. However, 
these adjustments are often crude approximations and are rarely revised by the users (subject 
with T1DM or carer) on a regular basis. 
In order to provide the required adaptability within a bolus calculator to be able to cope with 
the significant intra-subject variability in T1DM management, a Case-Based Reasoning 
approach [Aamodt 1994] was proposed by Herrero and colleagues [Herrero 2015a]. 
 
2.2- An Adaptive Insulin Bolus Calculator  
The proposed adaptive meal bolus calculator for closed-loop control is based on an existing 
technique referred to as Advanced Bolus Calculator for Diabetes Management (ABC4D) 
[Herrero 2015a, Herrero 2015b]. ABC4D has previously been validated in silico [Herrero 
2015a, Herrero 2015b] and tested in clinical trials [Pesl 2016b, Reddy 2016].  
ABC4D enhances currently existing bolus calculators by means of a combination of Case-
Based Reasoning [Aamodt 1994] and Run-To-Run Control [Wang 2009]. Periodic use of 
continuous glucose monitoring (CGM) data is required in order to perform a retrospective 
optimization of the bolus calculator parameters as described in [Herrero 2015b].  
 
Case-Based Reasoning 
Case-Based Reasoning (CBR) is an artificial intelligence problem solving framework that 
solves a newly encountered problem, based on the information obtained from previously 
solved problems and stored as cases in a case-base. A case is defined by  
𝐶𝑎𝑠𝑒: = {𝑃𝑟𝑜𝑏𝑙𝑒𝑚:, 𝑆𝑜𝑙𝑢𝑡𝑖𝑜𝑛:, 𝑂𝑢𝑡𝑐𝑜𝑚𝑒:}, (2) 
where Problemi is the description of the problem to be solved (insulin dosing for a breakfast 
with 70g of carbohydrates and planned moderate exercise); Solutioni is the solution to 
Problemi (administered insulin dose, i.e. parameters ICR and ISF of the bolus calculator); and 
Outcomei is the outcome resulting of applying Solutioni to Problemi (post-prandial excursion 
without hypoglycemia and mild hyperglycemia). 
CBR is usually described in four steps: Retrieve the most similar cases to the problem to be 
solved from the case-base; Reuse the solutions of retrieved cases; Revise the outcome of the 
applied solution to the new problem; and Retain the new problem if its solution is considered 
useful for solving future problems [Aamodt 1994]. Figure 2 show the four steps of the CBR 
cycle (Retrieve, Reuse, Revise, Retain) applied to the problem of meal insulin dosing using a 
bolus calculator. 
 
Figure 2. CBR cycle (Retrieve, Reuse, Revise, Retain) applied to the problem of meal insulin 
dosing using a bolus calculator. 
 
In ABC4D, cases are stored in a subject-specific case-base representing meal scenarios with 
significantly different insulin requirements (e.g. breakfast after exercise vs. dinner after 



































Cases are retrieved from the case-base by computing the Euclidian distance between the 
current problem and all the cases in the case-base and by selecting the case with the shorter 
distance [Herrero 2015a].  
If the retrieved case is different from the current scenario (e.g. breakfast with exercise vs. 
breakfast with exercise), its solution is reused (Reuse step) by applying a set of simple rules to 
guarantee that the applied solution is safe (e.g. increase ICR and ISF by 30%) and a new case 
is created for the new scenario. If the retrieved case is equal to the current scenario, then no 
new case is created. 
In order to perform the Revision step, the Run-to-Run algorithm proposed by Herrero et al. 
[Herrero 2015b] is employed, which adapt the solution of the retrieved, or newly created, case 
(i.e. ICR and ISF) when the glucose outcome is considered sub-optimal based on the analysis 
of the postprandial CGM measurements.  
Note that, unlike the traditional CBR approach [Aamodt 1994] where the solutions of the 
cases in the case-base are static, in ABC4D, such solutions (ICR and ISF) can be adapted if 
considered to be sub-optimal. This strategy partially solves the so-called problem of cold-start 
in CBR [Quijano-Sánchez 2012] (i.e. insufficient cases in the case-base) by initializing the 
case-base with a small set of sub-optimal, but safe, cases and letting the system converge 
towards an optimal solution while adapting solutions of existing cases and adding new cases 
to the case-base.  
 
Run-To-Run Algorithm 
Run-To-Run (R2R) is a control methodology designed to exploit repetitiveness in the process 
that is being controlled [Wang 2009]. Its purpose is to enhance performance, using a 
mechanism of trial and error. The simplest formulation of R2R may be, 
𝑢IJK = 𝑢I + 𝐾 · 𝑒𝑟𝑟𝑜𝑟,  (3) 
where u is the control action, K is a tuning gain and error is the tracking error defined as the 
difference between a measurement from the process and a set-point. 
The R2R algorithm used in revision step of the CBR algorithm in ABC4D is based on the 
hypothesis that, if the meal insulin bolus is not optimal, this is going to be reflected on the 
minimal glucose value achieved over the postprandial period, which in subjects with T1DM 
lasts around 5–6 h after a meal [ADA 2001]. Then, the meal insulin bolus can be adjusted 
based on the error between the minimal post-prandial glucose concentration (Gmin), obtained 
with a continuous glucose monitor over a predefined time window [t1, t2] (see Figure 3), and 
a glucose target (GT) preselected by the user or healthcare professional, which corresponds to 
the same glucose target in the bolus calculator (Equation (1)).  
Therefore, the adjusted bolus is calculated as 
𝐵IJK = 𝐵I + 𝐾 · 𝐺O:P − 𝐺Q ,  (4) 
where K·(Gmin- GT) is the extra insulin (Bextra1) that needs to be added (or subtracted) to the 
original bolus (Bk) in order to bring blood glucose levels back to the target (GT), and K is a 
tuning gain defined as K=1/ISF. 
In order to avoid unnecessary adaptations due to the inherent uncertainty in glucose 
management (e.g. sensor noise and carbohydrate estimation), a glucose target range [Gl, Gh] 
is defined where no adaptation is required if Gmin falls within this range (see Figure 3). For the 
same reason, the second term of Equation (1) (i.e. correction bolus) is set to zero if the 
glucose measurement at meal time (GM) falls within the glucose range [Gl, Gh]. Figure 3 
graphically represents how the error term (Gmin- GT) in Equation (4) is calculated. 
 
Figure 3. Graphical representation of the calculation of the error term (Gmin- GT) in Equation 
(4). tmeal corresponds to meal ingestion time. 
 
The proposed R2R algorithm for meal bolus adaptation is based on a second hypothesis that 
sustains that insulin-to-carbohydrate-ratio (ICR) and insulin sensitivity factor (ISF) are 
correlated [Walsh 2011] by the expression 
𝐼𝑆𝐹 = KSTU&#'
V.TX
,   (5) 
where 𝑊 is the weight of the subject (lbs).  




.  (6) 
However, Equation (6) is not fully suited to be used within the context of a closed-loop (CL) 
system for blood glucose control. Note that the CL controller can compensate for the lack of 
meal-priming bolus and bring glucose levels within the target range [Gl, Gh] over the time 
window [t1, t2], but the post-prandial glucose peak can still be significantly sub-optimal. 
Nonetheless, assuming that the CL controller is correctly tuned, the ABC4D R2R metric is 
still valid when Gmin falls below the target range. If Gmin falls within or above the target range, 














The new proposed metric is based on the hypothesis that, assuming that the CL controller is 
appropriately tuned, the insulin delivered by the CL controller during the postprandial period 
over the basal insulin, is insulin that should have been delivered by the meal-priming bolus. 
Thus, the bolus calculator parameters can be updated based on this additional insulin. 
 Let the insulin delivered by the CL controller over the basal insulin during a predefined 
postprandial time window [t3, t4] be defined as  
𝐵klmnoV 	= 	𝑚𝑖𝑛 𝐷 𝑘 ,mrms 𝐾V · 𝐵 , (7) 
where D(k) are the insulin doses delivered by the CL controller when glucose levels G(k) are 
above the glucose target range (G(k)>Gh), and K2 a tunable gain used to saturate Bextra2 to a 
maximum allowed dose of K2·B. Figure 4 graphically represents how Bextra2 in Equation (7) is 
calculated. Note that postprandial time windows [t1, t2] and [t3, t4] are tunable parameters 
and might have different lengths. 
 
 
Figure 4. Graphical representation of the calculation of the term Bextra2 in Equation (7). Solid 
and empty vertical bars represent insulin doses D(k) delivered by the CL controller when 
G(k)>Gh and G(k)<Gh respectively. 
 
Then, the updated ICR (ICRk+1), and consequently ISFk+1, can be easily obtained by replacing 
Bextra1 by Bextra2 in Equation (6). Note that, since the objective is to bring glucose levels within 
the target range [Gl, Gh], only the insulin delivered over G>Gh is considered in Equation (7).  
Finally, to filter potential outliers, the new ICR is obtained by computing the average of two 
consecutive ICR adaptations and the current value. Therefore, actual adaptations are only 
carried out every two adaptations for the same meal case. 
 
 
Finally, in order to integrate the presented adaptive meal bolus calculator (ABC) within a 
closed-loop (CL) controller two additional considerations need to be taken into account. First, 














(i.e. insulin-on-board), the insulin-on-board (IOB) term from Equation (1) and Equation (6) 
were omitted. Second, since the CL controller is meant to correct hyperglycemia during 
fasting condition, the correction bolus term from Equation (1) (second term) was omitted 
when GM> Gl. 
The reader is referred to Appendix A for details about the Imperial College Artificial 
Pancreas controller employed in this study. 
 
2.3- In Silico Evaluation under intra-day variability 
The latest version of the UVa-Padova T1DM simulator (v3.2) [Kovatchev 2009] was used to 
evaluate the proposed adaptive bolus calculator for closed-loop controllers. 11 adult subjects 
and 11 adolescent subjects were used for this purpose. The chosen basal insulin infusion rate 
for the virtual subjects was the one provided by the default insulin therapy of the simulator. 
The selected CGM and insulin pump models to perform the simulations were the Dexcom G4 
and Deltec Cozmo. A three-month scenario was selected in order to leave enough time to the 
meal bolus adaptation mechanism to converge. The selected daily pattern of carbohydrate 
dose intake was 7am (60g), 12pm (100g) and 6pm (80g). 
In order to test the benefits of the proposed technique, the Imperial College Artificial 
Pancreas (AP) controller with the adaptive meal bolus calculator (ABC-AP) was evaluated 
against the same controller without meal bolus adaptation (AP). 
 
Intra-day variability 
Intra-day variability was introduced to the simulator by modifying some of the parameters of 
the model described in [Dalla Man 2007]. In particular, meal variability was emulated by 
introducing meal-size variability (CV=10%), meal-time variability (STD=20) and uncertainty 
in the carbohydrate estimation (uniform distribution between -30% and +20%) [Brazeau 
2013]. Meal absorption rate (kabs) and carbohydrate bioavailability (f) were considered to be 
±30% and ±10% respectively. The 11 meals corresponding to each cohort were randomly 
assigned at each meal intake. Intra-subject variability in insulin absorption model parameter 
(kd, ka1, ka2) was assumed ±30% [Haidar 2013]. Insulin sensitivity parameters (Vmx, Kp3) were 
assumed to vary along the day following the sinusoidal pattern 
𝑝 𝑡 = 𝑝U + 0.3 · 𝑝U𝑠𝑖𝑛 2
x
Vr·TU
𝑡 + 2𝜋 · 𝑅𝑁𝐷,  (7) 
where p(t) is the corresponding time varying parameter (i.e. Vmx or kp3); p0 is the default 
parameter value in the simulator; and RND is a randomly uniformly generated number 
between 0 and 1. 
Note that despite all the variability introduced in the simulator, only three different cases were 
required within the CBR algorithm (i.e. breakfast, lunch and dinner).  
 
Controller tuning 
For this in silico study, the following tuning values were considered for the evaluation of the 
proposed algorithm: Gl = 80mg/dl; Gh=120 mg/dl; Gsp=100 mg/dl; t1=2h; t2=5h, t3=2h; 
t4=4h, K2=0.2. The rational for choosing such time windows was the fact that it usually takes 
about 2 hours to be able to say that a meal bolus is not enough to cover a meal due to the slow 
insulin pharmacokinetics (i.e. insulin-on-board), and that a postprandial glucose excursion for 
a standard mixed meal lasts around 5 hours [ADA 2001]. Note that these values could be 
individualized and such individualization could lead to superior glycemic outcomes. 
However, we wanted to prove that the proposed technique is still valid for a generic tuning. 
Regarding the CBR algorithm, since only three scenarios (i.e. cases) were considered 
(breakfast, lunch and dinner), the potential benefit of this algorithm could not be fully 
evaluated. Finally, the Imperial College Artificial Pancreas (AP) controller was tuned as 
described in Appendix A. 
 
Evaluation metrics 
The following glycemic metrics, which are widely accepted by the artificial pancreas 
community to evaluate glucose controllers [Maahs 2016], were selected for comparison 
purposes: mean blood glucose (BG); percentage time in glucose target range [70,180] mg/dl 
(%inT); percentage time below target (i.e. hypoglycemia) (%<T); percentage time above 
target (i.e. hyperglycemia) (%>T); glycemic variability indices: low blood glycemic index 
(i.e. risk of hypoglycemia) (LBGI), high blood glycemic index (i.e. risk of hyperglycemia) 
(HBGI), risk index (RI=LBGI+HBGI); and daily average of insulin delivered in units of 
insulin (TDI).  
 
3- Results	
Table 1 and Table 2 show the results corresponding to the 11 adults and 11 adolescents for 
each one of the evaluated control strategies (AP vs. ABC-AP). Figure 2 shows a comparison 
between AP and ABC-AP of the weekly evolution of three of the evaluated glycemic metrics 
(%inT, %<T and %>T) for the two studied cohorts. 
 
Table 1 – Glycemic results corresponding to the 11 adult subjects. 
 BG %inT %<T %>T RI LBGI HBGI TDI 






0.14±0.12 3.6±1.3 45.8±10.1 
ABC-AP 131.8±4.2 89.5±4.2 0.21±0.18 10.2±4.1 2.4±0.69 0.19±0.06 2.2±0.6 48.5±10.4 
p <0.001 <0.001 0.99 <0.001 <0.005 0.12 <0.005 0.002 
 
Table 2 - Glycemic results corresponding to the 11 adolescent subjects. 
 BG %inT %<T %>T RI LBGI HBGI TDI 
AP 158.2±21.4 65.9±12.9 2.2±2.7 31.7±13.1 
 
7.8±3.9 0.73±0.82 7.0±3.9 35.0±8.8 
ABC-AP 140.5±13.0 77.5±12.2 2.5±2.4 19.8±10.2 5.2±3.1 0.94±0.84 4.2±2.4 
 
38.3±10.2 
p <0.001 <0.001 0.6446 <0.001 <0.001 0.4 <0.001 <0.001 
 
 
Figure 2. Weekly evolution of the glycemic metrics %inT, %<T and %>T for the adult cohort 
(above) and the adolescent cohort (below) corresponding the AP controller without meal 
bolus adaptation (dashed red line) and the AP controller with meal bolus adaptation (ABC-
AP) method (solid blue line). Error bars represent the standard deviation. 
 
4- Discussion	
Integrating an adaptive meal bolus calculator within the Imperial College Artificial Pancreas 
controller (ABC-AP) significantly improves all the evaluated glycemic outcomes in a virtual 
T1D population (11 adults + 11 adolescents) when compared against the Imperial College AP 
without bolus adaptation over a three-month scenario with intra-day variability. It is 
important to note that the proposed adaptive meal bolus calculator is independent of the 
closed-loop controller employed and could be used within other artificial pancreas systems.  
It is also worth noting that the significant reduction in hyperglycemia was achieved without 
any increase in hypoglycemia – indeed in both the adult and adolescent there was a non-
significant reduction in time spent below target.  
Despite the significant intra-subject variability and uncertainty in carbohydrate intake 
estimation, the closed-loop controller was able to cope avoid remarkably well with 
hypoglycemia. Therefore, the inclusion of the adaptive meal bolus calculator did not 
introduce any improvement regarding time spent in hypoglycemia. 
Although statistically significant, the increase in total daily insulin delivered was not 
dramatically relevant (i.e. 3 U per day on average). This is an indicator that for this study, the 
most important factor for improving glycemic control is the way insulin was delivered and 
not the total amount.  
When analyzing the weekly evolution of the evaluated glycemic metrics, it was observed that 
glycemic metrics take about 8 weeks to converge without significant oscillations towards a 
steady state value and remain fairly stable along the simulation. This convergence rate could 
be increased by using a less conservative strategy when saturating/filtering the insulin-to-
carbohydrate ratio adaptation.  
In a real-life scenario, the convergence rate might take longer due to the consideration of 
more cases representing other scenarios such as exercise, alcohol consumption, hormone 
cycles or stress.  
Thanks to the additional intra-day variability introduced in the simulator, it was possible to 
evaluate the robustness of the proposed technique under conditions which might be not too far 
from a real-life scenario. Clinical trials to evaluate such a technique are currently in 
preparation. 
 
Appendix A - The Imperial College Artificial Pancreas Controller 
The Imperial College Artificial Pancreas (ICAP) controller has been previously in silico and 
clinically validated [Herrero 2012, Reddy 2014, Reddy 2015]. The original ICAP controller 
has as core component a mathematical model of the beta-cell physiology [Pedersen 2010]. In 
addition, it incorporates an insulin feedback term [Steil 2004] to avoid insulin stacking by 
compensating for delays associated with subcutaneous insulin delivery. It also includes a low-
glucose suspend (LGS) to minimize hypoglycemia. 
In this work, an updated version of ICAP is introduced, where the the original pancreatic 
insulin secretion model [Pedersen 2010] is replaced by a most recent model [Riz 2014]. The 
motivation for changing such model was it better performance in simulation studies as well as 
the reduced complexity of the new model which significantly speeds up the computations. 
The updated version of the ICAP controller is described by the equation 
𝑢 𝑡 = 𝑆𝑅 𝑡 + 	𝑆𝑅{ 	− 𝐾|𝐼}(𝑡),  (9) 
where SR is the pancreatic insulin secretion (SR) above basal secretion, SRb is the basal 
insulin secretion, and 𝐾|𝐼}	is the insulin feedback term, which is proportional (𝐾|) to the 
plasma insulin estimation 𝐼}	. 
As described in [Riz 2014], the pancreatic insulin secretion (SR) above basal secretion (SRb) 
is assumed proportional (m) to the amount X of readily releasable insulin in the beta-cells 
𝑆𝑅(𝑡) = 𝑚	𝑋(𝑡).  (10) 
The change in the insulin amount in the ready releasable pool (RRP) X results from the 
balance between the insulin secretion rate, the provision Y of insulin refilling the readily 
releasable pool, and recruitment of readily releasable insulin XD  
(m)
m
= −𝑚𝑋(𝑡) + 𝑌(𝑡) + 𝑋(𝑡),									𝑋(0) = 0, (11) 
where XD is responsible for the first phase of secretion and is assumed to be proportional to 









   (12) 
Remark: In the ICAP controller, the conditional statement in Equation (12) regarding the sign 
of the glucose derivative was eliminated. The rationale behind this modification is that delays 
in insulin absorption and glucose sensing due to the subcutaneous route make reducing 
insulin delivery when glucose is dropping desirable in order to minimize hypoglycemia.  




= −𝛼 𝑌(𝑡) 	− 	𝛽(𝐺(𝑡) 	− 	𝐺{) ,									𝑌(0) = 0, (13) 
where Gb represents the basal value of glucose, and 𝛼 and 𝛽 are parameters. 
Parameter 𝛽 is employed as a personalised tunable gain proportional to the subject’s insulin 
sensitivity factor (ISF) used to overcome inter-subject variability. In particular, the following 
correlation was employed for this study, 𝛽 = 0.0225/ISF, where IFS is expressed in mg/dl 
per U. 
For simulation purpose, the model was discretized using Euler method with an integration 
step of one minute. To attenuate the delays associated with subcutaneous glucose sensing 
[Facchinetti 2014], glucose measurements are forecasted 20 minute ahead using a linear 
regression of the last 6 glucose values (i.e. the preceding 30 minutes). The basal insulin term 
(SRb) is set to the subject’s basal insulin infusion profile. To tackle the perturbation 
introduced by the meals, a meal announcement strategy is used consisting of giving an insulin 
bolus calculated using a standard bolus calculator [Schmidt 2014] immediately before the 
ingestion of the meal.  
To minimise hypoglycaemia, a low-glucose suspend (LGS) algorithm is incorporated on top 
of the controller. This LGS algorithm reduces the insulin delivery proposed by the controller 
to 50% if the forecasted glucose value falls below a predefined threshold (TH1) and suspends 
the insulin delivery if it falls below a second lower predefined threshold (TH1). To prevent 
rebound hyperglycaemia, the insulin suspension is limited to 90 minutes, after which time the 
insulin delivery is resumed to 50% for 30 minutes and after this period total suspension is 
activated again if the hypoglycaemic condition is satisfied. It is important to remark that the 
LGS algorithm does not affect the meal bolus insulin. Figure 2 shows a schematic diagram of 
the ICAP controller. 
 
 
Figure 2. Block diagram of the ICAP controller, where inputs are the amount of ingested 
carbohydrates, the glucose concentration from a continuous glucose sensor, and the basal 
insulin rate for a given subject, and the output in the insulin dose to be delivered by the 
insulin pump. 
 
Table 3 shows the values for the controller parameters employed for the simulation performed 
in this study. Such parameters where selected based on in silico tests. mean The mean 
population presented in [Hovorka 2004] were considered for the employed insulin absorption 
pharmacokinetic (PK) model to estimate plasma insulin concentration (𝐼}). 
 




b (U per mg/dl) 0.0225/ISF 
KD (min) b·45 
Gb (mg/dl) 117 
Ky 50 
TH1 (mg/dl) 81 
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